All Updates

All Updates

icon
Filter
Earnings/results
Mirati Therapeutics beats analyst estimates in Q2 2023; announces USD 300 million underwritten public offering
Precision Medicine
Aug 8, 2023
This week:
Partnerships
Apple discloses use of AWS GenAI chips at re:Invent 2024 conference
Generative AI Infrastructure
Today
Product updates
AWS launches Automated Reasoning checks to combat AI hallucinations
Generative AI Infrastructure
Today
Product updates
Roonyx releases enhanced BNPL platform to facilitate secure transactions
Buy Now, Pay Later
Yesterday
Product updates
AWS announces next generation of SageMaker platform at re:Invent 2024
Generative AI Infrastructure
Yesterday
Product updates
Equal1 launches quantum controller chip for cryogenic computing
Quantum Computing
Yesterday
Partnerships
Exotec partners with BlueStar to deploy Skypod warehouse automation system
Logistics Tech
Yesterday
Partnerships
Amaero enters long-term supply agreement with Perryman
Additive Manufacturing
Yesterday
Product updates
Raise3D launches six new resins for DF2 DLP solution
Additive Manufacturing
Yesterday
M&A
Anzu Partners acquires voxeljet for EUR 20 million
Additive Manufacturing
Yesterday
Funding
Soda Health raises USD 50 million in oversubscribed Series B funding to scale operations
Health Benefits Platforms
Yesterday
Precision Medicine

Precision Medicine

Aug 8, 2023

Mirati Therapeutics beats analyst estimates in Q2 2023; announces USD 300 million underwritten public offering

Earnings/results

  • Mirati Therapeutics reported a Q2 2023 net loss per share of USD 3.04, beating estimates by 4.1% YoY. The biopharma's net loss rose 0.3% YoY to USD 176.9 million. Net product revenue was USD 13.4 million from the newly launched KRAZATI.

  • Operating expenses increased 10.1% YoY, driven by a 39.3% YoY rise in selling/admin costs from expanded headcount and KRAZATI commercialization. This was partially offset by a 3.2% YoY R&D spending decrease due to reduced sitravatinib clinical costs and lower share-based compensation.

  • Mirati announced an underwritten public offering of 9.7 million shares plus 1.1 million warrant shares, aiming to raise approximately USD 300 million. Net proceeds will fund drug development and leadership expansion and is expected to close on August 12, 2023.

  • The cash, cash equivalents, and short-term investments for June 2023 stood at USD 779.4 million compared to USD 1.1 billion at the end of Q4 2022. The company did not provide guidance for 2023.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.